October 2021

Context Therapeutics Completes $25M IPO

United States - Pennsylvania

Context Therapeutics, Inc., a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, completed its $25 million initial public offering (IPO) of 5,000,000 shares of common stock at public offering price of $5 per share. The common stock began trading on The Nasdaq Capital Market on October 19, 2021 under the ticker symbol CNTX. ThinkEquity LLC acted as the underwriter for the offering. Faegre Drinker represented Context Therapeutics in the transaction.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.